Results 1 to 10 of about 424,438 (249)

Drug costs in context: assessing drug costs in cost-of-illness analyses [PDF]

Drugs in Context, 2022
Cost-of-illness (COI) studies attempt to measure and describe the costs associated or attributed to a specific disease, but there are several considerations for measuring and interpreting drug costs estimates.
T Joseph Mattingly II, Shannon Weathers
doaj   +4 more sources

The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis [PDF]

Frontiers in Public Health, 2023
BackgroundIn April 2009, the Chinese government launched Zero Markup Drug Policy (ZMDP) to adjust medical institutions' revenue and expenditure structures.ObjectiveThis study evaluated the impact of implementing ZMDP (as an intervention) on the drug ...
Ruilin Wang, Ruilin Wang, Xinya Li, Xinya Li, Xinya Li, Xinya Li, Xinchun Gu, Qian Cai, Yayong Wang, Zhan-Miao Yi, Zhan-Miao Yi, Zhan-Miao Yi, Li-Chia Chen   +12 more
doaj   +2 more sources

Drug costs in Canada [PDF]

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2017
Kerry, Mansell, Yvonne, Shevchuk
europepmc   +7 more sources

A systematic review of observational studies evaluating costs of adverse drug reactions

ClinicoEconomics and Outcomes Research, 2016
Francisco Batel Marques,1,2 Ana Penedones,1,2 Diogo Mendes,1,2 Carlos Alves,1,2 1CHAD – Centre for Health Technology Assessment and Drug Research, AIBILI – Association for Innovation and Biomedical Research on Light and Image, 2School of ...
Batel Marques F, Penedones A, Mendes D, Alves C   +3 more
doaj   +2 more sources

Digital transformation, green finance, and pharmaceutical affordability in China: a health economics perspective [PDF]

Frontiers in Public Health
IntroductionDrug accessibility is a core challenge facing global public health systems, with financing costs directly affecting drug prices through cost-plus pricing mechanisms.
Jingdong Huang, Xinyi Zhang
doaj   +2 more sources

The challenges of access to innovative medicines with limited evidence in the European Union

Frontiers in Pharmacology, 2023
The European Medicines Agency (EMA) fosters access to innovative medicines through accelerated procedures and flexibility in the authorization requirements for diseases with unmet medical needs, such as many rare diseases as well as oncological diseases.
Antonio Vallano, Antonio Vallano, Antonio Vallano, Caridad Pontes, Caridad Pontes, Caridad Pontes, Antònia Agustí, Antònia Agustí   +7 more
doaj   +1 more source

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

Pharmaceuticals, 2021
This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is
Steven Simoens, Arnold G. Vulto, Pieter Dylst   +2 more
doaj   +1 more source

Treatment Access, Health Economics, and the Wave of a Magic Wand

Current Oncology, 2022
New drugs are expensive, in part due to excessive drug development costs. Governments are trying to reduce drug prices. This can delay access to effective agents. A country’s access to new drugs correlates with prices they agree to pay.
David J. Stewart, John-Peter Bradford, Gerald Batist   +2 more
doaj   +1 more source

Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil

Frontiers in Pharmacology, 2022
Background: Conventional synthetic disease-modifying antirheumatic drugs are the first-line treatment to inhibit the progression of psoriatic arthritis.
Ronaldo José Faria, Ronaldo José Faria, Francisca Janiclecia Rezende Cordeiro, Jéssica Barreto Ribeiro dos Santos, Jéssica Barreto Ribeiro dos Santos, Juliana Alvares-Teodoro, Augusto Afonso Guerra Júnior, Francisco de Assis Acurcio, Michael Ruberson Ribeiro da Silva, Michael Ruberson Ribeiro da Silva   +9 more
doaj   +1 more source

The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis

Pharmaceutics, 2021
High medication costs are one of the major barriers to patient adherence. Medication affordability might be improved by generic substitution. The aim of this study was to assess the effectiveness of the implementation of generic substitution mechanisms ...
Przemysław Kardas, Aneta Lichwierowicz, Filip Urbański, Beata Szadkowska-Opasiak, Ewa Karasiewicz, Paweł Lewek, Dominika Krupa, Marcin Czech   +7 more
doaj   +1 more source